Please ensure Javascript is enabled for purposes of website accessibility

MannKind Corp. Sinks Again On Bankruptcy Concerns

By George Budwell - Jan 6, 2016 at 9:12AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An analyst downgrade sends MannKind's shares spiraling down again.

Image source: MannKind.

What: Following yesterday's beating, MannKind's (MNKD 0.93%) shares fell another 14% in early morning trading on heavy volume after Piper Jaffray analyst Joshua Schimmer cut his price target on the stock from $1.50 down to $0.05. With Sanofi (SNY 1.08%) deciding to end its partnership with MannKind for the inhaled insulin product Afrezza yesterday, Schimmer thinks it's going to be extremely difficult for the struggling biotech to avoid bankruptcy at this point.

So what: MannKind's management held a conference call after the market closed yesterday trying to assuage investors' fears that the company might be on the verge of bankruptcy. After all, the biotech's cash runway is expected to be exhausted before year's end, and there's no obvious way the company can market Afrezza on its own. 

Now what: MannKind is reportedly trying to dig up another marketing partner for Afrezza to reverse the course of the drug's commercial trajectory. But that may be unrealistic at this stage. Sanofi has perhaps the best infrastructure in the business to handle the commercial launch of a diabetes product and the French drugmaker simply couldn't make it work.

Making matters worse, MannKind will now need to pay for the required post-marketing studies for Afrezza, or somehow convince a future partner to do so. As Afrezza's initial commercial launch was essentially a disaster -- leading to Sanofi's exit -- it's difficult to see why another pharma would be willing to take on this financial responsibility. In short, bankruptcy is a real possibility that shareholders need to consider in the wake of Sanofi terminating its partnership with MannKind. 

George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

MannKind Corporation Stock Quote
MannKind Corporation
$4.33 (0.93%) $0.04
Sanofi Stock Quote
$49.71 (1.08%) $0.53

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.